CEO Total Pay
$19.8M
FY2021 Summary Compensation
SRNE
2026 data Public-data reference. official source
Sorrento Therapeutics, Inc.
Open-data reference.
Chemicals & Pharmaceuticals · DE · FY2021
CEO-to-Worker Pay Ratio
152:1
High (Scale: 0–1000:1)
CEO Pay
$19.8M
Median Worker
$130,192
Compensation Pillar
CEO compensation breakdown — pay ratio 152× median worker (Dodd-Frank §953(b) disclosure)
Sorrento Therapeutics, Inc., a chemicals & pharmaceuticals company, reported a CEO-to-worker pay ratio of 152:1 in FY2021. CEO received total compensation of $19.8M, while the median employee earned $130,192 annually. This is above the Chemicals & Pharmaceuticals industry median of 44:1 across 185 companies. Data sourced from SEC EDGAR proxy (DEF 14A) filings.
CEO Compensation Breakdown — FY2021
Detailed breakdown not available.
| Component | Amount (USD) |
|---|---|
| Base Salary | — |
| Bonus | — |
| Stock Awards | — |
| Option Awards | — |
| Non-Equity Incentive Plan | — |
| Pension Value Change | — |
| Other Compensation | — |
| Total Compensation | $19.8M |
Source: SEC EDGAR Form DEF 14A — CIK 850261, FY2021 Summary Compensation Table.
Industry Comparison — Chemicals & Pharmaceuticals
This Company's Ratio
152:1
Industry Median Ratio
44:1
Industry Median CEO Pay
$7.8M
This CEO's Pay
$19.8M
Companies in Industry
185
vs. Industry Median
Above
Understanding This Pay Ratio
Sorrento Therapeutics, Inc.'s CEO-to-worker pay ratio of 152:1 means that earned 152 times more than the company's median employee in FY2021.
The median employee at Sorrento Therapeutics, Inc. earned $130,192 annually. At that wage, it would take a median employee approximately 152 years to earn what the CEO earned in a single year.
Pay Ratio
152:1
Elevated vs peers
Disclosure Transparency
1.0/5
Limited pay component reporting
Pay-Versus-Performance Disclosure
Under 17 CFR §229.402(v) (the Pay-Versus-Performance rule effective for fiscal years ending after December 16, 2022), issuers must reconcile Compensation Actually Paid (CAP) to Total Shareholder Return (TSR) over a multi-year window. The chart below visualizes the relationship between Sorrento Therapeutics, Inc.'s reported CAP and TSR for FY2021.
Pay vs Performance — FY2021 (Dodd-Frank §953(a) PvP disclosure)
Pay Composition
Equity-based pay (stock + options) 0.0%
Performance-linked (incentive + bonus) 0.0%
Fixed compensation (base salary) 0.0%
ISS QualityScore and Glass-Lewis voting guidelines weight performance-linked share of pay. The CII (Council of Institutional Investors) recommends ≥50% of CEO pay be tied to multi-year performance metrics.
What This 2021 Filing Tells Us About Sorrento Therapeutics, Inc.
According to the 2021 DEF 14A proxy statement filed with the SEC, Sorrento Therapeutics, Inc. (SRNE, CIK 850261) reported CEO 's total compensation at $19.8M. That figure is an aggregate of base salary (N/A). The median employee at the firm — the reference point mandated by Section 953(b) of the Dodd-Frank Act — earned $130,192 over the same fiscal year, producing the headline CEO-to-worker pay ratio of 152:1 that this page tracks.
Context matters when reading this ratio. Sorrento Therapeutics, Inc. operates in the Chemicals & Pharmaceuticals sector and is headquartered in DE. Across the Chemicals & Pharmaceuticals industry (SIC 28), 185 SEC-reporting companies disclosed pay ratios in FY2023, with a median of 44:1 and an average of 90:1. Median industry CEO pay was $7.8M, so Sorrento Therapeutics, Inc.'s $19.8M sits above that typical figure. That comparison is the fastest way to separate "the CEO is paid like peers" from "this company is an outlier."
Finally, a note on what these SEC numbers do and do not include. Total compensation reported under Item 402 of Regulation S-K reflects grant-date fair value for equity awards, not realized pay, so a CEO may eventually cash in more — or less — depending on stock performance and vesting. The pay ratio itself is calculated against a single median employee chosen under rules that allow statistical sampling, and companies may update methodology year to year. This proxy was filed on 2022-11-01; all figures on this page come directly from that public filing and can be verified against the DEF 14A on the SEC EDGAR system.
Key Data — FY2021
- CEO
- Total Compensation
- $19.8M
- Base Salary
- N/A
- Median Employee Pay
- $130,192
- Pay Ratio
- 152:1
- Filing Date
- 2022-11-01
Company Info
- Ticker
- SRNE
- CIK
- 850261
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2836
- State
- DE
Guides
Explore More
Data Source: This data is sourced from SEC EDGAR proxy statement (DEF 14A) filings. PlainCEOPay provides this publicly available information for informational purposes only. Not investment or financial advice. Verify with official SEC filings at sec.gov.
Frequently Asked Questions
What is the CEO pay ratio at Sorrento Therapeutics, Inc.? ▼
Sorrento Therapeutics, Inc.'s CEO-to-worker pay ratio is 152:1. CEO null earned $19.8M in FY2021, while the median employee earned $130,192.
How much does Sorrento Therapeutics, Inc.'s CEO earn? ▼
null, CEO of Sorrento Therapeutics, Inc. (SRNE), earned total compensation of $19.8M in fiscal year 2021, according to SEC proxy filings.
How does Sorrento Therapeutics, Inc.'s pay ratio compare to its industry? ▼
Sorrento Therapeutics, Inc.'s pay ratio of 152:1 is above the Chemicals & Pharmaceuticals industry median of 44:1. The industry has 185 companies reporting pay ratios.
Where does Sorrento Therapeutics, Inc.'s CEO pay data come from? ▼
All executive compensation data is sourced from SEC EDGAR DEF 14A proxy statement filings. Companies are required by the Dodd-Frank Act to disclose CEO-to-median-worker pay ratios annually. PlainCEOPay aggregates this publicly available data for easy comparison.
What is included in null's total compensation? ▼
Total compensation of $19.8M includes base salary, stock awards, option awards, non-equity incentive plan compensation, pension value changes, and other compensation as reported in the proxy filing summary compensation table.
How long would it take a median Sorrento Therapeutics, Inc. employee to earn the CEO's pay? ▼
At a median salary of $130,192, it would take the typical Sorrento Therapeutics, Inc. employee approximately 152 years to earn what CEO null earned in a single year ($19.8M in FY2021).
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- U.S. Census Bureau ACS — demographic + housing + income data. census.gov/programs-surveys/acs
- BLS Occupational Employment and Wage Statistics (OEWS) — wage + employment by occupation. bls.gov/oes
- BEA Regional Economic Accounts — GDP + personal income by state/metro. bea.gov/data/regional
- U.S. Census Bureau County Business Patterns — establishment + employment by industry. census.gov/cbp
- IRS Statistics of Income (SOI) — tax-return aggregate data. irs.gov/statistics
- data.gov — U.S. federal open-data portal — discovery layer for additional federal sources. data.gov
Related
Data sourced from $official public datasets. See our methodology for details. Retrieved and formatted by PlainCEOPay Editorial
